Sustained virological response against hepatitis C virus in a patient with Down's syndrome treated with interferon-β

DOI Web Site Web Site 20 References
  • Matsuda Toshiya
    Ehime University, School of Medicine
  • Furukawa Shinya
    Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine
  • Yokomoto Yuki
    Ehime University, School of Medicine
  • Abe Yosuke
    Ehime University, School of Medicine
  • Takagi Kohei
    Ehime University, School of Medicine
  • Habu Kyosuke
    Ehime University, School of Medicine
  • Kisaka Yoshiyasu
    Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine
  • Tokumoto Yoshio
    Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine
  • Mashiba Toshie
    Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine
  • Hirooka Masashi
    Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine
  • Abe Masanori
    Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine
  • Hiasa Yoichi
    Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine
  • Onji Morikazu
    Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine

Bibliographic Information

Other Title
  • ダウン症候群を合併したC型慢性肝炎にインターフェロン治療でウイルス学的著効が得られた1例
  • 症例報告 ダウン症候群を合併したC型慢性肝炎にインターフェロン治療でウイルス学的著効が得られた1例
  • ショウレイ ホウコク ダウン ショウコウグン オ ガッペイ シタ Cガタ マンセイ カンエン ニ インターフェロン チリョウ デ ウイルスガクテキ チョコウ ガ エラレタ 1レイ

Search this article

Abstract

A woman with Down's syndrome who developed liver damage due to hepatitis C virus (HCV) infection following surgery in childhood to treat a ventricular septal defect was treated with anti-HCV therapy. At age 25, liver function test suggested liver cirrhosis, and her heart condition was good. Since her prognosis was thought to be dependent on the course of the hepatitis C, she was treated with interferon (IFN) as an anti-HCV therapy. Achieving sustained virological response (SVR) in patients with Down's syndrome is known to be rare. However, she achieved SVR after 48 weeks of IFN-β monotherapy. Findings of HCV genotype 2a and a viral load of 3.2 log IU/mL are expected to be related to the good response to IFN, despite progressed liver fibrosis. Moreover, compliance with IFN-β administration was good. The prognosis for patients with Down's syndrome has recently improved. Anti-HCV therapy needs to be adapted for these patients, and IFN-β may be a suitable drug of choice.<br>

Journal

  • Kanzo

    Kanzo 53 (4), 201-205, 2012

    The Japan Society of Hepatology

References(20)*help

See more

Related Projects

See more

Keywords

Details 詳細情報について

Report a problem

Back to top